Evidence map›Paper›PMID 40368794›Full record

ArticleInternal medicine (Tokyo, Japan)2025

Differences in Organ Damage Based on Age at Onset in Idiopathic Inflammatory Myopathies: A Retrospective Multicenter MYKO Study.

Hideaki Tsuji, Yuki Aitani, Yudai Koshida, Keisuke Hirobe, Kazuma Yoshida, Atsubumi Ogawa, Yuto Nakakubo, Yoichi Nakayama, Tsuneyasu Yoshida, Yasuhiro Nohda and 10 more

Abstract readMulticenter Study
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Hideaki TsujiDepartment of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Japan.
Yuki AitaniDepartment of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Japan.
Yudai KoshidaDepartment of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Japan.
Keisuke HirobeDepartment of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Japan.
Kazuma YoshidaDepartment of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Japan.
Atsubumi OgawaDepartment of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Japan.
Yuto NakakuboDepartment of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Japan.
Yoichi NakayamaDepartment of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Japan.
Tsuneyasu YoshidaDepartment of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Japan.
Yasuhiro NohdaDepartment of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Japan.
Tsuneo SasaiDepartment of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Japan.
Hirofumi MiyakeDepartment of General Internal Medicine, Tenri Hospital, Japan.
Chifumi AkiyamaDepartment of Internal Medicine (IV), Division of Rheumatology, Osaka Medical and Pharmaceutical University, Japan.
Mahiro YamamotoDepartment of Internal Medicine (IV), Division of Rheumatology, Osaka Medical and Pharmaceutical University, Japan.
Katsumasa OeDepartment of Internal Medicine (IV), Division of Rheumatology, Osaka Medical and Pharmaceutical University, Japan.
Shogo MatsudaDepartment of Internal Medicine (IV), Division of Rheumatology, Osaka Medical and Pharmaceutical University, Japan.
Takayasu SuzukaDepartment of Internal Medicine (IV), Division of Rheumatology, Osaka Medical and Pharmaceutical University, Japan.
Ran NakashimaDepartment of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Japan.
Takuya KotaniDepartment of Internal Medicine (IV), Division of Rheumatology, Osaka Medical and Pharmaceutical University, Japan.
Akio MorinobuDepartment of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective To analyze the influence of age of the onset on myositis organ damage and to identify the factors influencing myositis organ damage, as clinical manifestations of myopathies differ by the age of onset and the background of patients. Methods Factors influencing organ damage [the Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index (SDI)] were identified using the Japanese multicenter myositis registry (MYKO, n=220). Factors influencing organ damage were identified using a multivariate analysis. SDI was compared among juvenile-onset (<20 years old), adolescent-onset (20-64 years), and elderly-onset (>64 years) groups. Results There was a correlation between the age at onset and the SDI score (Spearman's rank correlation coefficient ρ=0.28). Elderly patients exhibited more widespread organ damage, including neuropsychiatric, renal, pulmonary, cardiovascular, peripheral vascular, gastrointestinal, skin, and diabetes, whereas juvenile-onset patients exhibited musculoskeletal damage. Adolescent-onset patients had the lowest incidence of ocular and malignant damage. A regression analysis revealed that an older onset age (coefficient, β=0.03), longer disease duration (β=0.05), and total dose of glucocorticoid (β=3.35×10

Indexed as

MyositisAdolescentAdultAgedAge of OnsetFemaleHumansJapanMaleMiddle AgedRegistriesRetrospective StudiesYoung Adultidiopathic inflammatory myopathyjuvenile dermatomyositisjuvenile idiopathic inflammatory myopathyjuvenile polymyositisorgan damage

Identifiers

PMID40368794
PMCPMC12702551

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.